Document Detail

Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: implications for antiviral therapy.
MedLine Citation:
PMID:  21056499     Owner:  NLM     Status:  MEDLINE    
BACKGROUND & AIMS: We determined the virological profile in Chinese chronic hepatitis B (CHB) subjects and its implications regarding current treatment guidelines.
METHODS: A total of 1400 treatment-naïve CHB patients had their HBV DNA levels determined using the Cobas Taqman assay. Patient demographics, HBeAg status, and liver biochemistry were also recorded.
RESULTS: The subjects were predominantly male (62%), had a median age of 45 years, and 301 (22%) were HBeAg-positive. In subjects aged ≤ 25, 26-35, 36-45, 46-55, and >55 years, there was a decreasing trend of HBV DNA levels of 9.9, 9.3, 8.2, 7.4, and 7.3 log copies/ml, respectively (p<0.001), in HBeAg-positive subjects, while the pattern was reversed with HBV DNA levels of 3.7, 4.4, 4.7, 4.9, and 5.2 log copies/ml, respectively, in HBeAg-negative subjects (p<0.001). In HBeAg-negative subjects, the proportion of patients with elevated ALT compared to those with normal ALT was significantly higher in older age groups (p<0.001). In our study population, by applying the AASLD, EASL, and APASL guidelines, 64%, 99%, and 64% would be eligible for antiviral therapy, respectively, in HBeAg-positive patients (with elevated ALT), and 38%, 72%, and 43%, respectively, in HBeAg-negative patients (with elevated ALT). Up to 54% of patients over the age of 40 years would be recommended for liver biopsy to determine further eligibility for treatment.
CONCLUSIONS: For HBeAg-negative CHB, more patients had elevated ALT and a higher viral load with increasing age. Close monitoring is recommended in this group so that treatment may be considered. By applying the current treatment guidelines, a wide discrepancy can be observed in the proportion of patients eligible for treatment in the absence of histological data.
James Fung; Wai-Kay Seto; Ching-Lung Lai; John Yuen; Danny Ka-Ho Wong; Man-Fung Yuen
Related Documents :
18379139 - Retrospective evaluation of serum markers apri and ast/alt for assessing liver fibrosis...
2782649 - Comparative effects of halothane and isoflurane anesthesia on the ultrastructure of hum...
20658739 - Ultrasonographic examination of the liver circulation in patients with liver metastasis...
15986869 - A clinical-morphological study on cholestatic presentation of nonalcoholic fatty liver ...
1419619 - Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests.
9917439 - Clinical and genetic risk factors for cystic fibrosis-related liver disease.
16622719 - Twenty-four-week follow-up examination of a leukocytapheresis therapy in rheumatoid art...
9776479 - Individual variations in lymphocyte-responses to glucocorticoids in patients with bronc...
3484649 - Contrasting presentation and findings between patients with rheumatic complaints taking...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-10-19
Journal Detail:
Title:  Journal of hepatology     Volume:  54     ISSN:  1600-0641     ISO Abbreviation:  J. Hepatol.     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-01-18     Completed Date:  2011-04-25     Revised Date:  2012-08-24    
Medline Journal Info:
Nlm Unique ID:  8503886     Medline TA:  J Hepatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  195-200     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, Hong Kong.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alanine Transaminase / blood
DNA, Viral / analysis*
Hepatitis B e Antigens / analysis
Hepatitis B virus / genetics,  isolation & purification*
Hepatitis B, Chronic / drug therapy,  virology*
Middle Aged
Viral Load
Reg. No./Substance:
0/DNA, Viral; 0/Hepatitis B e Antigens; EC Transaminase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pre-operative liver biopsy in cirrhotic patients with early hepatocellular carcinoma represents a sa...
Next Document:  The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepati...